AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD Shareholder_NN Information_NN www_NN ._.
com_NN 126_CD Shareholder_NN Information_NN AstraZeneca_NNP 1999 2000 2001 2002_CD Ordinary_NNP Shares_NNP in_IN issue_NN millions_NNS At_IN year_NN end_NN 1,775_CD 1,766_CD 1,745_CD 1,719_CD Weighted_VBN average_NN for_IN year_NN 1,776_CD 1,768_CD 1,758_CD 1,733_CD Stock_NNP Market_NNP price_NN per_IN $_$ 0.25_CD Ordinary_NNP Share_NNP Highest_NNP pence_NN 2946 3600 3555 3625_CD Lowest_NNP pence_NN 2208 1926 2880 1799_CD At_IN year_NN end_NN pence_NN 2568 3375 3098 2220_CD 1_CD Earnings_NNS per_IN $_$ 0.25_CD Ordinary_NNP Share_NN before_IN exceptional_JJ items_NNS $_$ 1.63_CD $_$ 1.62_CD $_$ 1.73_CD $_$ 1.84_CD 1_CD Earnings_NNS per_IN $_$ 0.25_CD Ordinary_NNP Share_NNP basic_JJ $_$ 0.73_CD $_$ 1.30_CD $_$ 1.65_CD $_$ 1.64_CD 1_CD Earnings_NNS per_IN $_$ 0.25_CD Ordinary_NNP Share_NNP diluted_VBD $_$ 0.73_CD $_$ 1.30_CD $_$ 1.65_CD $_$ 1.64_CD Dividends_NNPS $_$ 0.70_CD $_$ 0.70_CD $_$ 0.70_CD $_$ 0.70_CD For_IN the_DT period_NN 1_CD January_NNP 1999_CD to_TO 31_CD December_NNP 1999_CD except_IN for_IN Stock_NNP Market_NNP prices_NNS which_WDT are_VBP for_IN the_DT period_NN from_IN 6_CD April_NNP 1999_CD to_TO 31_CD December_NNP 1999_CD ._.
In_IN addition_NN ,_, shareholders_NNS received_VBD a_DT distribution_NN of_IN shares_NNS in_IN Syngenta_NNP AG_NNP as_IN a_DT dividend_NN in_IN specie_NN in_IN respect_NN of_IN the_DT demerger_NN of_IN Zeneca_NNP Agrochemicals_NNPS ._.
1_CD Earnings_NNS per_IN share_NN have_VBP been_VBN restated_VBN for_IN the_DT effect_NN of_IN the_DT adoption_NN of_IN FRS19_NNP Deferred_NNP Tax_NNP Zeneca_NNP 1999_CD Ordinary_NNP Shares_NNP in_IN issue_NN millions_NNS At_IN period_NN end_NN 953_CD Weighted_JJ average_NN for_IN period_NN 951_CD Stock_NNP Market_NNP price_NN per_IN 25_CD pence_NN Ordinary_NNP Share_NNP Highest_NNP pence_NN 3037_CD Lowest_NNP pence_NN 2406_CD At_IN period_NN end_NN pence_NN 3037_CD For_IN the_DT period_NN from_IN 1_CD January_NNP 1999_CD to_TO 6_CD April_NNP 1999_CD Astra_NNP 1999_CD Ordinary_NNP Shares_NNP in_IN issue_NN millions_NNS At_IN period_NN end_NN 1,643_CD Weighted_VBN average_NN for_IN period_NN 1,643_CD Stock_NNP Market_NNP price_NN per_IN Astra_NNP A_NNP Share_NNP Highest_NNP SEK_NNP 190_CD Lowest_NNP SEK_NNP 154_CD At_IN period_NN end_NN SEK_NNP 190_CD Stock_NNP Market_NNP price_NN per_IN Astra_NNP B_NNP Share_NNP Highest_NNP SEK_NNP 190_CD Lowest_NNP SEK_NNP 154_CD At_IN period_NN end_NN SEK_NNP 190_CD For_IN the_DT period_NN from_IN 1_CD January_NNP 1999_CD to_TO 6_CD April_NNP 1999_CD Percentage_NN analysis_NN at_IN 31_CD December_NNP 2002_CD of_IN issued_VBN share_NN capital_NN By_IN size_NN of_IN account_NN No._NN ._.
In_IN addition_NN there_EX were_VBD approximately_RB 46,000_CD holders_NNS of_IN American_JJ Depositary_NNP Receipts_NNPS ADRs_NNPS representing_VBG 5.31_CD %_NN of_IN the_DT issued_VBN share_NN capital_NN and_CC 156,000_CD holders_NNS of_IN shares_NNS held_VBN under_IN the_DT VPC_NNP Services_NNPS Agreement_NNP representing_VBG 23.56_CD %_NN of_IN the_DT issued_VBN share_NN capital_NN ._.
The_DT ADRs_NNPS ,_, each_DT of_IN which_WDT is_VBZ equivalent_JJ to_TO one_CD Ordinary_NNP Share_NN ,_, are_VBP issued_VBN by_IN JPMorgan_NNP Chase_NNP Bank_NNP ._.
com_NN 127_CD AstraZeneca_NNP PLC_NNP Since_IN April_NNP 1999_CD ,_, following_VBG the_DT AstraZeneca_NNP merger_NN ,_, the_DT principal_JJ markets_NNS for_IN trading_NN in_IN the_DT shares_NNS of_IN AstraZeneca_NNP PLC_NNP are_VBP the_DT London_NNP ,_, Stockholm_NNP and_CC New_NNP York_NNP Stock_NNP Exchanges_NNPS ._.
The_DT table_NN below_IN sets_NNS forth_RB ,_, for_IN the_DT four_CD quarters_NNS of_IN 2001_CD and_CC for_IN the_DT first_JJ two_CD quarters_NNS and_CC last_JJ six_CD months_NNS of_IN 2002_CD the_DT reported_VBN high_JJ and_CC low_JJ share_NN prices_NNS of_IN AstraZeneca_NNP PLC_NNP ,_, on_IN the_DT following_VBG bases_NNS :_: for_IN shares_NNS listed_VBN on_IN the_DT London_NNP Stock_NNP Exchange_NNP LSE_NNP the_DT reported_VBN high_JJ and_CC low_JJ middle_JJ market_NN closing_VBG quotations_NNS are_VBP derived_VBN from_IN The_DT Daily_NNP Official_NNP List_NN :_: for_IN shares_NNS listed_VBN on_IN the_DT Stockholm_NNP Stock_NNP Exchange_NNP SSE_NNP the_DT high_JJ and_CC low_JJ closing_NN sales_NNS prices_NNS are_VBP as_IN stated_VBN in_IN the_DT Official_NNP List_NN :_: for_IN American_JJ Depositary_NNP Shares_NNP ADS_NNPS listed_VBN on_IN the_DT New_NNP York_NNP Stock_NNP Exchange_NNP the_DT reported_VBN high_JJ and_CC low_JJ sales_NNS prices_NNS are_VBP as_IN reported_VBN by_IN Dow_NNP Jones_NNP ADR_NNP quotations_NNS ._.
The_DT average_JJ price_NN paid_VBN per_IN share_NN in_IN 2002_CD was_VBD 2818_CD pence_NN ._.
Between_IN 1999_CD and_CC 2001_CD a_DT total_NN of_IN 37.1_CD million_CD Ordinary_NNP Shares_NNP were_VBD re-purchased_JJ ,_, and_CC subsequently_RB canceled_VBN ,_, at_IN an_DT average_JJ price_NN of_IN 2910_CD pence_NN per_IN share_NN for_IN a_DT consideration_NN ,_, including_VBG expenses_NNS ,_, of_IN $_$ 1,615_CD m._FW The_DT excess_NN of_IN the_DT consideration_NN over_IN the_DT nominal_JJ value_NN was_VBD charged_VBN against_IN the_DT profit_NN and_CC loss_NN account_NN reserve_NN ._.
Shares_NNP issued_VBD in_IN respect_NN of_IN share_NN schemes_NNS totalled_VBD 1.7_CD million_CD ._.
In_IN 1999_CD in_IN connection_NN with_IN the_DT merger_NN ,_, AstraZenecas_NNP share_NN capital_NN was_VBD redenominated_VBN into_IN US_NNP dollars_NNS ._.
On_IN 6_CD April_NNP 1999_CD ,_, Zeneca_NNP shares_NNS were_VBD canceled_VBN and_CC US_NNP dollar_NN shares_NNS issued_VBN ,_, credited_VBN as_IN fully_RB paid_VBN on_IN the_DT basis_NN of_IN one_CD dollar_NN share_NN for_IN each_DT Zeneca_NNP share_NN then_RB held_VBD ._.
This_DT was_VBD achieved_VBN by_IN a_DT reduction_NN of_IN capital_NN under_IN section_NN 135_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD ._.
Upon_IN the_DT reduction_NN of_IN capital_NN becoming_VBG effective_JJ ,_, all_DT issued_VBN and_CC unissued_VBN Zeneca_NNP shares_NNS were_VBD canceled_VBN and_CC the_DT sum_NN arising_VBG as_IN a_DT result_NN thereof_RB credited_VBD to_TO a_DT special_JJ reserve_NN which_WDT was_VBD converted_VBN into_IN US_NNP dollars_NNS at_IN the_DT rate_NN of_IN exchange_NN prevailing_VBG on_IN the_DT record_NN date_NN ._.
This_DT US_NNP dollar_NN reserve_NN was_VBD then_RB applied_VBN in_IN paying_VBG up_RP at_IN par_JJ newly_RB created_VBN US_NNP dollar_NN shares_NNS ._.
At_IN the_DT same_JJ time_NN as_IN the_DT US_NNP dollar_NN shares_NNS were_VBD issued_VBN ,_, the_DT Company_NN issued_VBN 50,000_CD Redeemable_JJ Preference_NN Shares_NNS for_IN cash_NN at_IN par_NN ._.
The_DT Redeemable_JJ Preference_NN Shares_NNS carry_VBP limited_JJ class_NN voting_NN rights_NNS and_CC no_DT dividend_NN rights_NNS ._.
This_DT class_NN of_IN shares_NNS is_VBZ also_RB capable_JJ of_IN redemption_NN at_IN par_NN at_IN the_DT option_NN of_IN the_DT Company_NN on_IN the_DT giving_VBG of_IN seven_CD days_NNS written_VBN notice_NN to_TO the_DT registered_VBN holder_NN of_IN the_DT shares_NNS ._.
A_DT total_NN of_IN 826_CD million_CD AstraZeneca_NNP shares_NNS were_VBD issued_VBN to_TO Astra_NNP shareholders_NNS who_WP accepted_VBD the_DT merger_NN offer_NN before_IN the_DT final_JJ closing_NN date_NN ,_, 21_CD May_NNP 1999_CD ._.
AstraZeneca_NNP received_VBD acceptances_NNS from_IN Astra_NNP shareholders_NNS representing_VBG 99.6_CD per_IN cent_NN of_IN Astras_NNP shares_NNS and_CC the_DT remaining_VBG 0.4_CD per_IN cent_NN was_VBD acquired_VBN in_IN 2000_CD for_IN cash_NN ._.
com_NN 128_CD Shareholder_NN Information_NN continued_VBD Major_JJ shareholdings_NNS On_IN 29_CD January_NNP 2003_CD not_RB more_JJR than_IN one_CD month_NN prior_RB to_TO the_DT date_NN of_IN the_DT Notice_NNP of_IN Annual_JJ General_NNP Meeting_VBG the_DT following_VBG had_VBD disclosed_VBN an_DT interest_NN in_IN the_DT issued_VBN Ordinary_NNP Share_NNP capital_NN of_IN the_DT Company_NN in_IN accordance_NN with_IN the_DT requirements_NNS of_IN Sections_NNS 198-208_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD :_: Date_NN of_IN disclosure_NN Percentage_NN of_IN issued_VBN Shareholder_NN Number_NN of_IN shares_NNS to_TO Company_NNP share_NN capital_NN The_DT Capital_NNP Group_NNP Companies_NNS ,_, Inc._NNP 204,812,653_CD 14_CD Jan_NNP 2003_CD 11.92_CD %_NN Investor_NN AB_NNP 91,545,308_CD 16_CD Apr_NNP 1999_CD 5.33_CD %_NN Putnam_NNP Investment_NNP Management_NNP ,_, LLC_NNP and_CC The_DT Putnam_NNP Advisory_NNP Company_NNP ,_, LLC_NNP 52,643,485_CD 8_CD Feb_NNP 2002_CD 3.06_CD %_NN Legal_NNP &_CC General_NNP Investment_NNP Management_NNP Limited_NNP 52,518,020_CD 13_CD Jun_NN 2002_CD 3.06_CD %_NN No_DT other_JJ person_NN held_VBD a_DT notifiable_JJ interest_NN in_IN shares_NNS ,_, comprising_VBG 3_CD %_NN or_CC more_JJR of_IN the_DT issued_VBN Ordinary_NNP Share_NNP capital_NN of_IN the_DT Company_NN ,_, appearing_VBG in_IN the_DT register_NN of_IN interests_NNS in_IN shares_NNS maintained_VBN under_IN the_DT provisions_NNS of_IN Section_NN 211_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD ._.
Significant_JJ changes_NNS in_IN the_DT percentage_NN ownership_NN held_VBN by_IN major_JJ shareholders_NNS during_IN the_DT past_JJ three_CD years_NNS are_VBP set_VBN out_RP below_IN ._.
Major_JJ shareholders_NNS do_VBP not_RB have_VB different_JJ voting_NN rights_NNS ._.
Since_IN the_DT date_NN of_IN disclosure_NN to_TO the_DT Company_NN ,_, the_DT interest_NN of_IN any_DT person_NN listed_VBN above_IN in_IN the_DT Ordinary_NNP Shares_NNP of_IN the_DT Company_NN may_MD have_VB increased_VBN or_CC decreased_VBN ._.
No_DT requirement_NN to_TO notify_VB the_DT Company_NN of_IN any_DT increase_NN or_CC decrease_NN would_MD have_VB arisen_VBN unless_IN the_DT holding_VBG moved_VBD up_RP or_CC down_RP through_IN a_DT whole_JJ number_NN percentage_NN level_NN ._.
Percentage_NN of_IN issued_VBN share_NN capital_NN Shareholder_NN 29_CD Jan_NNP 2003_CD 17_CD Feb_NNP 2002_CD 9_CD Feb_NNP 2001_CD 14_CD Mar_NNP 2000_CD In_IN AstraZeneca_NNP In_IN AstraZeneca_NNP In_IN AstraZeneca_NNP In_IN AstraZeneca_NNP The_NNP Capital_NNP Group_NNP Companies_NNS ,_, Inc._NNP 11.92_CD %_NN 11.09_CD %_NN 10.02_CD %_NN 7.80_CD %_NN Investor_NN AB_NNP 5.33_CD %_NN 5.25_CD %_NN 5.18_CD %_NN 5.20_CD %_NN Putnam_NNP Investment_NNP Management_NNP ,_, LLC_NNP and_CC The_DT Putnam_NNP Advisory_NNP Company_NNP ,_, LLC_NNP 3.06_CD %_NN 3.02_CD %_NN 3.00_CD %_NN 3.00_CD %_NN Legal_NNP &_CC General_NNP Investment_NNP Management_NNP Limited_NNP 3.06_CD %_NN 3.00_CD %_NN 3.00_CD %_NN 3.00_CD %_NN AstraZeneca_NNP PLC_NNP American_NNP Depositary_NNP Shares_NNP each_DT representing_VBG one_CD Ordinary_NNP Share_NNP evidenced_VBD by_IN American_JJ Depositary_NNP Receipts_NNPS issued_VBN by_IN JPMorgan_NNP Chase_NNP Bank_NNP ,_, as_IN depositary_JJ ,_, are_VBP listed_VBN on_IN the_DT New_NNP York_NNP Stock_NNP Exchange_NNP ._.
As_IN of_IN 29_CD January_NNP 2003_CD ,_, the_DT proportion_NN of_IN Ordinary_NNP Shares_NNP represented_VBN by_IN American_JJ Depositary_NNP Shares_NNP was_VBD 5.32_CD %_NN of_IN the_DT Ordinary_NNP Shares_NNP outstanding_JJ ._.
Number_NN of_IN registered_VBN holders_NNS of_IN Ordinary_NNP Shares_NNP as_IN of_IN 29_CD January_NNP 2003_CD :_: In_IN the_DT US_NNP 804_CD Total_JJ 176,842_CD Number_NN of_IN record_NN holders_NNS of_IN American_JJ Depositary_NNP Receipts_NNPS as_IN of_IN 29_CD January_NNP 2003_CD :_: In_IN the_DT US_NNP 3,133_CD Total_JJ 3,167_CD So_RB far_RB as_IN the_DT Company_NN is_VBZ aware_JJ ,_, it_PRP is_VBZ neither_DT directly_RB nor_CC indirectly_RB owned_VBN nor_CC controlled_VBN by_IN one_CD or_CC more_JJR corporations_NNS or_CC by_IN any_DT government_NN ._.
com_NN 129_CD As_IN of_IN 29_CD January_NNP 2003_CD the_DT total_NN amount_NN of_IN the_DT Companys_NNP voting_NN securities_NNS owned_VBN by_IN Directors_NNS and_CC Officers_NNS of_IN the_DT Company_NN was_VBD :_: Title_NN of_IN class_NN Amount_NNP owned_VBD Per_IN cent_NN of_IN class_NN $_$ 0.25_CD shares_NNS Ordinary_NNP Shares_NNP 508,201_CD 0.03_CD %_NN The_DT Company_NN does_VBZ not_RB know_VB of_IN any_DT arrangements_NNS the_DT operation_NN of_IN which_WDT might_MD result_VB in_IN a_DT change_NN in_IN the_DT control_NN of_IN the_DT Company_NN ._.
Related_VBN party_NN transactions_NNS During_IN the_DT period_NN 1_CD January_NNP 2003_CD to_TO 29_CD January_NNP 2003_CD there_EX were_VBD no_DT transactions_NNS ,_, loans_NNS ,_, or_CC proposed_VBN transactions_NNS between_IN the_DT Company_NN and_CC any_DT related_JJ parties_NNS which_WDT were_VBD material_NN to_TO either_CC the_DT Company_NN or_CC the_DT related_JJ party_NN ,_, or_CC which_WDT were_VBD unusual_JJ in_IN their_PRP$ nature_NN or_CC conditions_NNS ._.
See_VB also_RB Note_VB 36_CD Statutory_NNP and_CC other_JJ information_NN ._.
Options_NNS to_TO purchase_VB securities_NNS from_IN registrant_JJ or_CC subsidiaries_NNS a_DT As_IN of_IN 29_CD January_NNP 2003_CD ,_, options_NNS outstanding_JJ to_TO subscribe_VB for_IN Ordinary_NNP Shares_NNP of_IN $_$ 0.25_CD of_IN the_DT Company_NN were_VBD :_: Number_NN of_IN shares_NNS Subscription_NNP price_NN Normal_JJ expiry_NN date_NN 34,608,810_CD 630p-3487p_JJ 2003-2012_CD The_DT weighted_JJ average_JJ subscription_NN price_NN of_IN options_NNS outstanding_JJ at_IN 29_CD January_NNP 2003_CD was_VBD 3000p_CD ._.
All_DT options_NNS were_VBD granted_VBN under_IN Company_NN employee_NN schemes_NNS ._.
b_NN Included_VBN in_IN paragraph_NN a_DT are_VBP options_NNS granted_VBN to_TO Directors_NNS and_CC Officers_NNS of_IN AstraZeneca_NNP as_IN follows_VBZ :_: Number_NN of_IN shares_NNS Subscription_NNP price_NN Normal_JJ expiry_NN date_NN 1,562,652_CD 748p-3487p_JJ 2004-2012_CD c_NN Included_VBN in_IN paragraph_NN b_NN are_VBP options_NNS granted_VBN to_TO individually_RB named_VBN Directors_NNS ._.
Details_NNS of_IN these_DT option_NN holdings_NNS as_IN at_IN 31_CD December_NNP 2002_CD are_VBP shown_VBN in_IN the_DT Directors_NNS Remuneration_NNP Report_NNP ._.
During_IN the_DT period_NN 1_CD January_NNP 2003_CD to_TO 29_CD January_NNP 2003_CD no_DT Director_NNP exercised_VBN any_DT options_NNS ._.
Dividend_NN payments_NNS The_DT record_NN date_NN for_IN the_DT second_JJ interim_JJ dividend_NN for_IN 2002_CD payable_JJ on_IN 7_CD April_NNP 2003_CD in_IN the_DT UK_NNP ,_, US_NNP and_CC Sweden_NNP is_VBZ 21_CD February_NNP 2003_CD ._.
Shares_NNP trade_NN ex-dividend_NN on_IN the_DT London_NNP and_CC Stockholm_NNP Stock_NNP Exchanges_NNPS from_IN 19_CD February_NNP 2003_CD and_CC ADRs_NNPS trade_NN ex-dividend_NN on_IN the_DT New_NNP York_NNP Stock_NNP Exchange_NNP from_IN the_DT same_JJ date_NN ._.
Future_JJ dividends_NNS will_MD normally_RB be_VB paid_VBN as_IN follows_VBZ :_: The_DT record_NN date_NN for_IN the_DT first_JJ interim_JJ dividend_NN for_IN 2003_CD payable_JJ on_IN 6_CD October_NNP 2003_CD in_IN the_DT UK_NNP ,_, US_NNP and_CC Sweden_NNP is_VBZ 22_CD August_NNP 2003_CD ._.
First_NNP interim_JJ :_: Announced_JJ end_NN of_IN July_NNP and_CC paid_VBN in_IN October_NNP Second_NNP interim_NN :_: Announced_JJ end_NN of_IN January_NNP and_CC paid_VBN in_IN April_NNP Registrar_NNP and_CC Transfer_NNP Office_NNP The_NNP AstraZeneca_NNP Registrar_NNP Lloyds_NNP TSB_NNP Registrars_NNPS The_DT Causeway_NNP Worthing_NNP West_NNP Sussex_NNP BN99_NNP 6DA_NNP Telephone_NNP 0870 600 3956_CD Shareview_NNP AstraZenecas_NNP shareholders_NNS with_IN internet_NN access_NN may_MD visit_VB www_NN ._.
co._FW uk_FW and_CC register_VB their_PRP$ details_NNS to_TO create_VB a_DT portfolio_NN ._.
Shareview_NNP is_VBZ a_DT free_JJ and_CC secure_JJ on-line_JJ service_NN from_IN Lloyds_NNP TSB_NNP Registrars_NNPS that_WDT gives_VBZ access_NN to_TO shareholdings_NNS including_VBG balance_NN movements_NNS ,_, indicative_JJ share_NN prices_NNS and_CC information_NN about_IN recent_JJ dividends_NNS ._.
Results_NNS Unaudited_JJ trading_NN results_NNS of_IN AstraZeneca_NNP in_IN respect_NN of_IN the_DT first_JJ three_CD months_NNS of_IN 2003_CD will_MD be_VB published_VBN on_IN 30_CD April_NNP 2003_CD and_CC results_NNS in_IN respect_NN of_IN the_DT first_JJ six_CD months_NNS of_IN 2003_CD will_MD be_VB published_VBN on_IN 24_CD July_NNP 2003_CD ._.
Documents_NNS on_IN display_NN The_DT Memorandum_NNP and_CC Articles_NNPS of_IN Association_NNP of_IN the_DT Company_NN and_CC other_JJ documents_NNS concerning_VBG the_DT Company_NN which_WDT are_VBP referred_VBN to_TO in_IN this_DT document_NN may_MD be_VB inspected_VBN at_IN the_DT Companys_NNPS registered_VBD office_NN at_IN 15_CD Stanhope_NNP Gate_NNP ,_, London_NNP W1K_NNP 1LN_NNP ._.
com_NN 130_CD Shareholder_NN Information_NN continued_VBD Taxation_NNP for_IN US_NNP residents_NNS For_IN US_NNP federal_JJ income_NN tax_NN purposes_NNS ,_, the_DT Shares_NNP or_CC ADRs_NNPS ._.
The_DT gain_NN or_CC loss_NN will_MD generally_RB The_DT following_VBG summary_NN of_IN the_DT principal_JJ UK_NNP dividend_NN paid_VBN and_CC ,_, if_IN a_DT US_NNP resident_NN be_VB US_PRP source_NN income_NN or_CC loss_NN ._.
US_NNP resident_NN and_CC certain_JJ US_NNP tax_NN consequences_NNS of_IN shareholder_NN elects_NNS under_IN the_DT Convention_NNP to_TO shareholders_NNS should_MD consult_VB their_PRP$ own_JJ tax_NN ownership_NN of_IN Ordinary_NNP Shares_NNP or_CC ADRs_NNPS held_VBD claim_NN a_DT foreign_JJ tax_NN credit_NN with_IN respect_NN to_TO the_DT advisors_NNS about_IN the_DT treatment_NN of_IN capital_NN gains_NNS ,_, as_IN capital_NN assets_NNS by_IN US_NNP resident_NN shareholders_NNS UK_NNP withholding_NN ,_, the_DT associated_VBN Tax_NNP Credit_NNP which_WDT may_MD be_VB taxed_VBN at_IN lower_JJR rates_NNS than_IN is_VBZ based_VBN on_IN current_JJ UK_NNP and_CC US_NNP federal_JJ Amount_NNP are_VBP includible_JJ in_IN gross_JJ income_NN by_IN US_NNP ordinary_JJ income_NN for_IN non-corporate_JJ taxpayers_NNS income_NN tax_NN law_NN and_CC practice_NN and_CC in_IN part_NN on_IN resident_NN shareholders_NNS and_CC ,_, for_IN foreign_JJ tax_NN and_CC capital_NN losses_NNS ,_, the_DT deductibility_NN of_IN which_WDT representations_NNS of_IN JPMorgan_NNP Chase_NNP Bank_NNP as_IN credit_NN limitation_NN purposes_NNS ,_, are_VBP foreign_JJ source_NN may_MD be_VB limited_VBN ._.
Depositary_NNP for_IN ADRs_NNPS and_CC assumes_VBZ that_IN each_DT income_NN ,_, treated_VBN separately_RB ,_, together_RB with_IN obligation_NN in_IN the_DT deposit_NN agreement_NN among_IN other_JJ items_NNS of_IN passive_JJ income_NN or_CC ,_, in_IN the_DT case_NN UK_NNP inheritance_NN tax_NN the_DT Company_NN ,_, the_DT Depositary_NNP and_CC the_DT holders_NNS of_IN certain_JJ holders_NNS ,_, financial_JJ services_NNS income_NN ._.
Under_IN the_DT current_JJ Double_RB Taxation_NNP Estates_NNP from_IN time_NN to_TO time_NN of_IN ADRs_NNPS and_CC any_DT related_JJ The_DT UK_NNP withholding_NN is_VBZ treated_VBN as_IN a_DT foreign_JJ Convention_NNP the_DT Estate_NNP Tax_NNP Convention_NNP agreement_NN will_MD be_VB performed_VBN in_IN accordance_NN income_NN tax_NN which_WDT may_MD ,_, subject_JJ to_TO certain_JJ between_IN the_DT US_NNP and_CC the_DT UK_NNP ,_, Ordinary_NNP Shares_NNP with_IN its_PRP$ terms_NNS ._.
The_DT US_NNP Treasury_NNP has_VBZ limitations_NNS and_CC restrictions_NNS ,_, be_VB eligible_JJ for_IN or_CC ADRs_NNPS held_VBN by_IN an_DT individual_JJ shareholder_NN expressed_VBD concerns_NNS that_IN parties_NNS to_TO whom_WP credit_NN against_IN a_DT US_NNP resident_NN shareholders_NNS US_PRP who_WP is_VBZ domiciled_VBN for_IN the_DT purposes_NNS of_IN the_DT ADRs_NNS are_VBP pre-released_JJ may_MD be_VB taking_VBG actions_NNS federal_JJ income_NN tax_NN liability_NN or_CC deductible_JJ by_IN Estate_NNP Tax_NNP Convention_NNP in_IN the_DT US_NNP ,_, and_CC is_VBZ not_RB that_WDT are_VBP inconsistent_JJ with_IN the_DT claiming_VBG ,_, by_IN US_NNP such_JJ shareholders_NNS in_IN computing_VBG their_PRP$ taxable_JJ for_IN the_DT purposes_NNS of_IN the_DT Estate_NNP Tax_NNP Convention_NNP holders_NNS of_IN ADRs_NNS ,_, of_IN foreign_JJ tax_NN credits_NNS for_IN US_NNP income_NN for_IN a_DT US_NNP resident_NN shareholder_NN who_WP a_DT national_JJ of_IN the_DT UK_NNP ,_, will_MD generally_RB not_RB be_VB federal_JJ income_NN tax_NN purposes_NNS ._.
Accordingly_RB ,_, the_DT elects_NNS to_TO include_VB the_DT associated_VBN Tax_NNP Credit_NNP subject_NN to_TO the_DT UK_NNP inheritance_NN tax_NN on_IN the_DT analysis_NN of_IN the_DT creditability_NN of_IN UK_NNP taxes_NNS Amount_NNP in_IN income_NN ._.
individuals_NNS death_NN or_CC on_IN a_DT chargeable_JJ gift_NN of_IN described_VBN below_IN could_MD be_VB affected_VBN by_IN future_JJ the_DT Ordinary_NNP Shares_NNP or_CC ADRs_NNPS during_IN the_DT actions_NNS that_WDT may_MD be_VB taken_VBN by_IN the_DT US_NNP Treasury_NNP ._.
The_DT election_NN described_VBN in_IN the_DT preceding_VBG individuals_NNS lifetime_NN provided_VBD that_IN any_DT paragraph_NN will_MD not_RB be_VB available_JJ under_IN the_DT New_NNP applicable_JJ US_NNP federal_JJ gift_NN or_CC estate_NN tax_NN liability_NN UK_NNP and_CC US_NNP income_NN taxes_NNS and_CC tax_NN treaties_NNS Convention_NNP and_CC ,_, accordingly_RB ,_, no_DT foreign_JJ tax_NN is_VBZ paid_VBN ,_, unless_IN the_DT Ordinary_NNP Shares_NNP or_CC ADRs_NNPS affecting_VBG remittance_NN of_IN dividends_NNS credit_NN for_IN the_DT related_JJ UK_NNP withholding_NN will_MD be_VB are_VBP part_NN of_IN the_DT business_NN property_NN of_IN a_DT Under_IN the_DT current_JJ Double_RB Taxation_NNP Income_NNP available_JJ under_IN the_DT New_NNP Convention_NNP with_IN permanent_JJ establishment_NN of_IN the_DT individual_NN in_IN Convention_NNP the_DT Convention_NNP between_IN the_DT respect_NN to_TO dividends_NNS paid_VBN to_TO US_NNP resident_NN the_DT UK_NNP or_CC ,_, in_IN the_DT case_NN of_IN a_DT shareholder_NN who_WP UK_NNP and_CC the_DT US_NNP ,_, US_NNP resident_NN individuals_NNS who_WP shareholders_NNS ._.
performs_VBZ independent_JJ personal_JJ services_NNS ,_, are_VBP the_DT beneficial_JJ owners_NNS of_IN dividends_NNS on_IN pertain_NN to_TO a_DT fixed_VBN base_NN situated_VBN in_IN the_DT UK_NNP ._.
Ordinary_NNP Shares_NNP ,_, or_CC ADRs_NNS representing_VBG Shareholders_NNS whose_WP$ holdings_NNS are_VBP effectively_RB Where_WRB the_DT ADRs_NNPS or_CC Ordinary_NNP Shares_NNP have_VBP Ordinary_NNP Shares_NNP ,_, in_IN UK_NNP corporations_NNS are_VBP connected_VBN with_IN a_DT permanent_JJ establishment_NN been_VBN placed_VBN in_IN trust_NN by_IN a_DT settlor_NN who_WP ,_, at_IN the_DT generally_RB entitled_VBN to_TO a_DT tax_NN credit_NN payment_NN in_IN or_CC fixed_VBN base_NN in_IN the_DT UK_NNP ,_, or_CC who_WP are_VBP time_NN of_IN settlement_NN ,_, was_VBD a_DT US_NNP resident_NN respect_NN of_IN dividends_NNS equal_JJ to_TO one-ninth_JJ corporations_NNS also_RB resident_NN in_IN the_DT UK_NNP for_IN the_DT shareholder_NN ,_, the_DT ADRs_NNPS or_CC Ordinary_NNP Shares_NNP will_MD 1_CD 9th_CD of_IN the_DT dividend_NN paid_VBD the_DT Tax_NNP Credit_NNP purpose_NN of_IN the_DT Convention_NNP ,_, are_VBP not_RB entitled_VBN to_TO generally_RB not_RB be_VB subject_JJ to_TO UK_NNP inheritance_NN tax_NN Amount_NNP ._.
This_DT tax_NN credit_NN payment_NN is_VBZ reduced_VBN payment_NN of_IN the_DT Tax_NNP Credit_NNP Amount_NNP nor_CC are_VBP unless_IN the_DT settlor_NN ,_, at_IN the_DT time_NN of_IN settlement_NN ,_, by_IN a_DT UK_NNP withholding_VBG the_DT UK_NNP withholding_NN of_IN they_PRP subject_VBP to_TO any_DT deductions_NNS from_IN the_DT was_VBD not_RB domiciled_VBN in_IN the_DT US_NNP and_CC was_VBD a_DT UK_NNP up_IN to_TO 15_CD %_NN of_IN the_DT gross_JJ dividend_NN paid_VBN ._.
In_IN the_DT exceptional_JJ case_NN where_WRB the_DT Therefore_RB ,_, a_DT US_NNP holder_NN will_MD not_RB actually_RB receive_VB Ordinary_NNP Shares_NNP or_CC ADRs_NNPS are_VBP subject_JJ both_DT to_TO any_DT payment_NN of_IN this_DT credit_NN ._.
Taxation_NNP on_IN capital_NN gains_NNS UK_NNP inheritance_NN tax_NN and_CC to_TO US_NNP federal_JJ gift_NN or_CC Under_IN the_DT Convention_NNP and_CC the_DT New_NNP estate_NN tax_NN ,_, the_DT Estate_NNP Tax_NNP Convention_NNP US_NNP resident_JJ corporate_JJ shareholders_NNS are_VBP Convention_NNP each_DT contracting_NN state_NN may_MD in_IN generally_RB provides_VBZ for_IN double_JJ taxation_NN to_TO be_VB generally_RB treated_VBN in_IN the_DT same_JJ way_NN as_IN general_JJ tax_NN capital_NN gains_NNS in_IN accordance_NN with_IN relieved_VBN by_IN means_NNS of_IN credit_NN relief_NN ._.
individuals_NNS provided_VBD that_DT either_CC alone_RB ,_, or_CC the_DT provisions_NNS of_IN its_PRP$ domestic_JJ law_NN ._.
Under_IN together_RB with_IN associated_VBN corporations_NNS ,_, they_PRP present_VBP UK_NNP law_NN ,_, individuals_NNS who_WP are_VBP neither_DT do_VBP not_RB control_VB directly_RB or_CC indirectly_RB 10_CD %_NN or_CC resident_NN nor_CC ordinarily_RB resident_NN in_IN the_DT UK_NNP ,_, and_CC more_JJR of_IN the_DT voting_NN shares_NNS of_IN the_DT Company_NN companies_NNS which_WDT are_VBP not_RB resident_JJ in_IN the_DT UK_NNP and_CC do_VB not_RB constitute_VB investment_NN or_CC holding_NN will_MD not_RB be_VB liable_JJ to_TO UK_NNP tax_NN on_IN capital_NN gains_NNS companies_NNS ,_, 25_CD %_NN or_CC more_JJR of_IN the_DT capital_NN of_IN made_VBN on_IN the_DT disposal_NN of_IN their_PRP$ Ordinary_NNP Shares_NNP which_WDT is_VBZ owned_VBN ,_, directly_RB or_CC indirectly_RB ,_, by_IN or_CC ADRs_NNPS ,_, unless_IN such_JJ Ordinary_NNP Shares_NNP or_CC persons_NNS that_WDT are_VBP not_RB individuals_NNS resident_NN in_IN ,_, ADRs_NNS are_VBP held_VBN in_IN connection_NN with_IN a_DT trade_NN ,_, and_CC are_VBP not_RB nationals_NNS of_IN ,_, the_DT US_NNP ._.
profession_NN or_CC vocation_NN carried_VBD on_IN in_IN the_DT UK_NNP through_IN a_DT branch_NN or_CC agency_NN ._.
The_DT UK_NNP and_CC the_DT US_NNP have_VBP signed_VBN a_DT new_JJ A_DT US_NNP resident_NN shareholder_NN will_MD recognize_VB double_JJ taxation_NN convention_NN the_DT New_JJ capital_NN gain_NN or_CC loss_NN for_IN US_NNP federal_JJ income_NN tax_NN Convention_NNP ,_, which_WDT must_MD be_VB ratified_VBN by_IN the_DT purposes_NNS on_IN the_DT sale_NN or_CC exchange_NN of_IN the_DT UK_NNP Parliament_NNP and_CC the_DT US_NNP Senate_NNP before_IN its_PRP$ Ordinary_NNP Shares_NNP or_CC ADRs_NNPS in_IN the_DT same_JJ manner_NN provisions_NNS enter_VBP into_IN force_NN ._.
No_DT assurance_NN can_MD as_RB such_JJ holder_NN would_MD on_IN the_DT sale_NN or_CC exchange_NN be_VB provided_VBN as_RB to_TO when_WRB the_DT New_NNP Convention_NNP of_IN any_DT other_JJ shares_NNS held_VBD as_IN capital_NN assets_NNS ._.
When_WRB the_DT Convention_NNP a_DT result_NN ,_, a_DT US_NNP resident_NN shareholder_NN will_MD ceases_VBZ to_TO apply_VB ,_, US_NNP resident_NN shareholders_NNS will_MD generally_RB recognize_VB capital_NN gain_NN or_CC loss_NN for_IN US_NNP no_RB longer_RB be_VB entitled_VBN to_TO the_DT Tax_NNP Credit_NNP Amount_NNP federal_JJ income_NN tax_NN purposes_NNS equal_JJ to_TO the_DT because_IN the_DT New_NNP Convention_NNP does_VBZ not_RB difference_NN between_IN the_DT amount_NN realized_VBD and_CC provide_VB for_IN that_DT entitlement_NN ._.
such_JJ holders_NNS adjusted_VBN basis_NN in_IN the_DT Ordinary_NNP AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD Shareholder_NN Information_NN www_NN ._.
com_NN 131_CD Taxation_NNP for_IN US_NNP residents_NNS continued_VBD Exchange_NNP controls_NNS and_CC other_JJ limitations_NNS affecting_VBG security_NN holders_NNS a_DT There_EX are_VBP no_DT governmental_JJ laws_NNS ,_, decrees_NNS or_CC regulations_NNS in_IN the_DT UK_NNP restricting_VBG the_DT import_NN or_CC export_NN of_IN capital_NN or_CC affecting_VBG the_DT remittance_NN of_IN dividends_NNS ,_, interest_NN or_CC other_JJ payments_NNS to_TO non-resident_JJ holders_NNS of_IN Ordinary_NNP Shares_NNP or_CC ADRs_NNPS ._.
However_RB ,_, a_DT 1.5_CD %_NN stamp_NN duty_NN reserve_NN tax_NN is_VBZ payable_JJ upon_IN the_DT deposit_NN of_IN Ordinary_NNP Shares_NNP in_IN connection_NN with_IN the_DT creation_NN of_IN but_CC not_RB subsequent_JJ dealing_NN in_IN ADRs_NNS ._.
This_DT is_VBZ in_IN lieu_NN of_IN the_DT normal_JJ 0.5_CD %_NN stamp_NN duty_NN on_IN all_DT purchases_NNS of_IN Ordinary_NNP Shares_NNP ._.
b_NN There_EX are_VBP no_DT limitations_NNS under_IN English_JJ law_NN or_CC the_DT Companys_NNP Memorandum_NNP and_CC Articles_NNPS of_IN Association_NNP on_IN the_DT right_NN of_IN non-resident_JJ or_CC foreign_JJ owners_NNS to_TO be_VB the_DT registered_VBN holders_NNS of_IN and_CC to_TO vote_VB Ordinary_NNP Shares_NNP or_CC to_TO be_VB registered_VBN holders_NNS of_IN notes_NNS or_CC debentures_NNS of_IN Zeneca_NNP Wilmington_NNP Inc._NNP ._.
Exchange_NNP rates_NNS For_IN the_DT periods_NNS up_IN to_TO April_NNP 1999_CD ,_, Astra_NNP accounted_VBD for_IN and_CC reported_VBD its_PRP$ results_NNS in_IN Swedish_JJ kronor_NNS ,_, whereas_IN Zeneca_NNP accounted_VBD for_IN and_CC reported_VBD its_PRP$ results_NNS in_IN sterling_NN ._.
Consistent_JJ with_IN AstraZenecas_NNP decision_NN to_TO publish_VB its_PRP$ Financial_NNP Statements_NNP in_IN US_NNP dollars_NNS ,_, the_DT financial_JJ information_NN in_IN this_DT document_NN has_VBZ been_VBN translated_VBN from_IN kronor_NNS and_CC sterling_NN into_IN US_NNP dollars_NNS at_IN the_DT following_VBG applicable_JJ exchange_NN rates_NNS :_: SEK_NNP USD_NNP USD_NNP GBP_NNP Average_JJ rates_NNS profit_NN and_CC loss_NN account_NN ,_, cash_NN flow_NN 1995_CD 7.1100_CD 1.5796_CD 1996_CD 6.7000_CD 1.5525_CD 1997_CD 7.6225_CD 1.6386_CD 1998_CD 7.9384_CD 1.6603_CD 1999_CD 8.2189_CD 1.6247_CD End_NN of_IN year_NN spot_NN rates_NNS balance_VBP sheet_NN 1995_CD 6.6500_CD 1.5500_CD 1996_CD 6.8400_CD 1.6900_CD 1997_CD 7.8500_CD 1.6600_CD 1998_CD 8.0400_CD 1.6600_CD 1999_CD 8.5130_CD 1.6185_CD The_DT following_VBG information_NN relating_VBG to_TO average_JJ and_CC spot_NN exchange_NN rates_NNS used_VBN by_IN AstraZeneca_NNP is_VBZ provided_VBN for_IN convenience_NN :_: SEK_NNP USD_NNP USD_NNP GBP_NNP Average_JJ rates_NNS profit_NN and_CC loss_NN account_NN ,_, cash_NN flow_NN 2000_CD 8.9103_CD 1.5341_CD 2001_CD 10.3235_CD 1.4447_CD 2002_CD 9.8558_CD 1.4817_CD End_NN of_IN year_NN spot_NN rates_NNS balance_VBP sheet_NN 2000_CD 9.5390_CD 1.4925_CD 2001_CD 10.5420_CD 1.4501_CD 2002_CD 8.7700_CD 1.6093_CD AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD Shareholder_NN Information_NN www_NN ._.
com_NN 132_CD Shareholder_NN Information_NN continued_VBD Definitions_NNS In_IN this_DT Annual_JJ Report_NNP and_CC Form_NN 20-F_NN the_DT following_JJ words_NNS and_CC expressions_NNS shall_MD ,_, unless_IN the_DT context_NN otherwise_RB requires_VBZ ,_, have_VBP the_DT following_VBG meanings_NNS :_: ADR_NNP American_NNP Depositary_NNP Receipt_NNP evidencing_VBG title_NN to_TO an_DT ADS_NNPS ADS_NNPS American_NNP Depositary_NNP Share_NNP representing_VBG one_CD underlying_VBG Ordinary_NNP Share_NNP Depositary_NNP JPMorgan_NNP Chase_NNP Bank_NNP ,_, as_IN depositary_NN under_IN the_DT deposit_NN agreement_NN pursuant_JJ to_TO which_WDT the_DT ADRs_NNPS are_VBP issued_VBN Directors_NNS The_DT Directors_NNS of_IN the_DT Company_NN Company_NN AstraZeneca_NNP PLC_NNP AstraZeneca_NNP ,_, AstraZeneca_NNP Group_NNP or_CC the_DT Group_NNP The_NNP Company_NNP and_CC its_PRP$ subsidiaries_NNS Ordinary_NNP Shares_NNP Ordinary_NNP Shares_NNP of_IN $_$ 0.25_CD each_DT in_IN the_DT capital_NN of_IN the_DT Company_NN LSE_NNP London_NNP Stock_NNP Exchange_NNP Limited_NNP NYSE_NNP New_NNP York_NNP Stock_NNP Exchange_NNP ,_, Inc._NNP ._.
SSE_NNP Stockholm_NNP Stock_NNP Exchange_NNP Pound_NNP sterling_NN ,_, GBP_NNP ,_, pence_NN or_CC p_VB References_NNS to_TO UK_NNP currency_NN SEK_NNP ,_, kronor_NNS References_NNS to_TO Swedish_JJ currency_NN UK_NNP United_NNP Kingdom_NNP of_IN Great_NNP Britain_NNP and_CC Northern_NNP Ireland_NNP US_NNP dollar_NN ,_, US$_$ ,_, USD_NNP or_CC $_$ References_NNPS to_TO US_NNP currency_NN US_NNP United_NNP States_NNPS of_IN America_NNP FDA_NNP Food_NNP and_CC Drug_NNP Administration_NNP of_IN the_DT US_NNP Figures_NNS in_IN parentheses_NNS in_IN tables_NNS and_CC financial_JJ statements_NNS are_VBP used_VBN to_TO represent_VB negative_JJ numbers_NNS ._.
Except_IN where_WRB otherwise_RB indicated_VBN ,_, figures_NNS included_VBD in_IN this_DT report_NN relating_VBG to_TO pharmaceutical_JJ product_NN market_NN sizes_NNS and_CC market_NN shares_NNS are_VBP obtained_VBN from_IN syndicated_VBN industry_NN sources_NNS ,_, primarily_RB IMS_NNP Health_NNP IMS_NNP ,_, a_DT market_NN research_NN firm_NN internationally_RB recognized_VBN by_IN the_DT pharmaceutical_JJ industry_NN ._.
The_DT 2002_CD market_NN share_NN figures_NNS included_VBD in_IN this_DT report_NN are_VBP based_VBN primarily_RB on_IN data_NNS obtained_VBN from_IN an_DT online_JJ IMS_NNP database_NN ._.
IMS_NNP data_NNS may_MD differ_VB from_IN that_DT compiled_VBN by_IN the_DT Group_NNP with_IN respect_NN to_TO its_PRP$ own_JJ products_NNS ._.
Of_IN particular_JJ significance_NN in_IN this_DT regard_NN are_VBP the_DT following_NN :_: 1_CD AstraZeneca_NNP publishes_VBZ its_PRP$ financial_JJ results_NNS on_IN a_DT financial_JJ year_NN and_CC quarterly_JJ interim_JJ basis_NN ,_, whereas_IN IMS_NNP issues_VBZ its_PRP$ data_NNS on_IN a_DT monthly_JJ and_CC quarterly_JJ basis_NN :_: 2_CD the_DT online_NN IMS_NNP database_NN is_VBZ updated_VBN quarterly_JJ and_CC uses_VBZ the_DT average_JJ exchange_NN rates_NNS for_IN the_DT relevant_JJ quarter_NN :_: 3_CD IMS_NNP data_NNS from_IN the_DT US_NNP is_VBZ not_RB adjusted_VBN for_IN Medicaid_NNP and_CC similar_JJ state_NN rebates_NNS :_: and_CC 4_CD IMS_NNP sales_NNS data_NNS is_VBZ compiled_VBN using_VBG actual_JJ wholesaler_NN data_NNS and_CC data_NNS from_IN statistically_RB representative_JJ panels_NNS of_IN retail_JJ and_CC hospital_NN pharmacies_NNS ,_, which_WDT data_NNS are_VBP then_RB projected_VBN by_IN IMS_NNP to_TO give_VB figures_NNS for_IN national_JJ markets_NNS ._.
References_NNS to_TO prevalence_NN of_IN disease_NN have_VBP been_VBN derived_VBN from_IN a_DT variety_NN of_IN sources_NNS and_CC are_VBP not_RB intended_VBN to_TO be_VB indicative_JJ of_IN the_DT current_JJ market_NN or_CC any_DT potential_JJ market_NN for_IN AstraZenecas_NNP pharmaceutical_JJ products_NNS since_IN ,_, among_IN other_JJ things_NNS ,_, there_EX may_MD be_VB no_DT correlation_NN between_IN the_DT prevalence_NN of_IN a_DT disease_NN and_CC the_DT number_NN of_IN individuals_NNS who_WP are_VBP treated_VBN for_IN such_JJ disease_NN ._.
com_NN 133_CD Terms_NNS used_VBN in_IN the_DT Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ US_NNP equivalent_NN or_CC brief_JJ description_NN Accruals_NNP Accrued_VBN expenses_NNS Allotted_NNP Issued_NNP Bank_NNP borrowings_NNS Payable_JJ to_TO banks_NNS Called-up_JJ share_NN capital_NN Issued_VBN share_NN capital_NN Capital_NN allowances_NNS Tax_NNP term_NN equivalent_NN to_TO US_NNP tax_NN depreciation_NN allowances_NNS Creditors_NNPS Liabilities_NNPS payables_NNS Current_JJ instalments_NNS of_IN loans_NNS Long_JJ term_NN debt_NN due_JJ within_IN one_CD year_NN Debtors_NNS Receivables_NNPS and_CC prepaid_JJ expenses_NNS Earnings_NNS Net_JJ income_NN Finance_NNP lease_NN Capital_NN lease_NN Fixed_VBN asset_NN investments_NNS Non-current_JJ investments_NNS Freehold_NNP Ownership_NN with_IN absolute_JJ rights_NNS in_IN perpetuity_NN Interest_NN receivable_NN Interest_NN income_NN Interest_NN payable_JJ Interest_NN expense_NN Loans_VBZ Long_JJ term_NN debt_NN Prepayments_NNS Prepaid_JJ expenses_NNS Profit_NN Income_NNP Profit_NNP and_CC loss_NN account_NN Income_NN statement_NN consolidated_JJ statement_NN of_IN income_NN Reserves_NNS Retained_VBN earnings_NNS Short_JJ term_NN investments_NNS Redeemable_JJ securities_NNS and_CC short_JJ term_NN deposits_NNS Share_NN premium_NN account_NN Premiums_NNS paid_VBN in_IN excess_NN of_IN par_JJ value_NN of_IN Ordinary_NNP Shares_NNP Statement_NNP of_IN Total_NNP Recognised_NNP Statement_NNP of_IN Comprehensive_NNP Income_NNP Gains_NNS and_CC Losses_NNS Stocks_NNS Inventories_NNS Tangible_JJ fixed_VBN assets_NNS Property_NN ,_, plant_NN and_CC equipment_NN Turnover_NN Sales_NNS revenues_NNS
